Serotonin and pulmonary hypertension-from bench to bedside?

被引:74
作者
MacLean, Margaret R. [1 ]
Dempsie, Yvonne [1 ]
机构
[1] Univ Glasgow, Fac Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland
基金
英国生物技术与生命科学研究理事会;
关键词
SMOOTH-MUSCLE-CELLS; 5-HYDROXYTRYPTAMINE TRANSPORTER GENE; MEDIATED VASOCONSTRICTION; CONVERGING EVIDENCE; GERMLINE MUTATIONS; RECEPTOR; DEXFENFLURAMINE; FENFLURAMINE; BMPR2; HYPERPLASIA;
D O I
10.1016/j.coph.2009.02.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The serotonin hypothesis of pulmonary arterial hypertension (PAH) arose owing to anorexigens, acting as indirect serotinergic agonists, causing PAH. However, it is now thought that serotonin plays an important role in the pathobiology of PAH per se. The rate-limiting enzyme in the synthesis of peripheral serotonin is tryptophan hydroxylase 1 (TPH1), serotonin can mediate pulmonary arterial smooth muscle cell proliferation via the serotonin transporter (SERT) and serotonin can induce pulmonary vasoconstriction via the 5-HT1B receptor in man. There is evidence that TPH1, SERT and 5-HT1B expression/activity can be upregulated in clinical PAH. This review discusses recent evidence implicating serotonin in the development of experimental and clinical PAH and suggests potential therapeutic targets.
引用
收藏
页码:281 / 286
页数:6
相关论文
共 56 条
[1]  
Alexander SPH, 2005, BRIT J PHARMACOL, V144, pS1
[2]   Mutations in the gene encoding bone morphogenetic protein receptor 2 in patients with idiopathic pulmonary arterial hypertension [J].
Baloira, Adolfo ;
Vilarino, Carlos ;
Leiro, Virginia ;
Valverde, Diana .
ARCHIVOS DE BRONCONEUMOLOGIA, 2008, 44 (01) :29-34
[3]   Serotonin 5-HT2B receptor loss of function mutation in a patient with fenfluramine-associated primary pulmonary hypertension [J].
Blanpain, C ;
Le Poul, E ;
Parma, J ;
Knoop, C ;
Detheux, M ;
Parmentier, M ;
Vassart, G ;
Abramowicz, MJ .
CARDIOVASCULAR RESEARCH, 2003, 60 (03) :518-528
[4]   Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine2B receptors in mice [J].
Callebert, J ;
Esteve, JM ;
Hervé, P ;
Peoc'h, K ;
Tournois, C ;
Drouet, L ;
Launay, JM ;
Maroteaux, L .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (02) :724-731
[5]   Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells -: Role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization [J].
Cogolludo, A ;
Moreno, L ;
Lodi, F ;
Frazziano, G ;
Cobeño, L ;
Tamargo, J ;
Perez-Vizcaino, F .
CIRCULATION RESEARCH, 2006, 98 (07) :931-938
[6]   Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice [J].
Dempsie, Yvonne ;
Morecroft, Ian ;
Welsh, David J. ;
MacRitchie, Neil A. ;
Herold, Nigel ;
Loughlin, Lynn ;
Nilsen, Margaret ;
Peacock, Andrew J. ;
Harmar, Anthony ;
Bader, Michael ;
MacLean, Margaret R. .
CIRCULATION, 2008, 117 (22) :2928-2937
[7]   Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene [J].
Eddahibi, S ;
Hanoun, N ;
Lanfumey, L ;
Lesch, KP ;
Raffestin, B ;
Hamon, M ;
Adnot, S .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (11) :1555-1562
[8]   Cross talk between endothelial and smooth muscle cells in pulmonary hypertension - Critical role for serotonin-induced smooth muscle hyperplasia [J].
Eddahibi, S ;
Guignabert, C ;
Barlier-Mur, AM ;
Dewachter, L ;
Fadel, E ;
Dartevelle, P ;
Humbert, M ;
Simonneau, G ;
Hanoun, N ;
Saurini, F ;
Hamon, M ;
Adnot, S .
CIRCULATION, 2006, 113 (15) :1857-1864
[9]  
Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI200112805
[10]   Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension [J].
Fujiwara, Maya ;
Yagi, Hisato ;
Matsuoka, Rumiko ;
Akimoto, Kaoru ;
Furutani, Michiko ;
Imamura, Shin-Ichiro ;
Uehara, Ritei ;
Nakayama, Tomotaka ;
Takao, Atsuyoshi ;
Nakazawa, Makoto ;
Saji, Tsutomu .
CIRCULATION JOURNAL, 2008, 72 (01) :127-133